Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR

K. K. Goncz, A. Colosimo, B. Dallapiccola, L. Gagné, K. Hong, G. Novelli, D. Papahadjopoulos, T. Sawa, H. Schreier, J. Wiener-Kronish, Z. Xu, D. C. Gruenert

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The development of gene targeting strategies for specific modification of genomic DNA in human somatic cells has provided a potential gene therapy for the treatment of inherited diseases. One approach, small fragment homologous replacement (SFHR), directly targets and modifies specific genomic sequences with small fragments of exogenous DNA (400-800 bp) that are homologous to genomic sequences except for the desired modification. This approach has been effective for the in vitro modification of exon 10 in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human airway epithelial cells. As another step in the development of SFHR for gene therapy, studies were carried out to target and modify specific genomic sequences in exon 10 of the mouse CFTR (mCFTR) in vivo. Small DNA fragments (783 bp), homologous to mCFTR except for a 3-bp deletion (ΔF508) and a silent mutation which introduces a unique restriction site (Kpnl), were instilled into the lungs of normal mice using four different DNA vehicles (AVE, LipofectAMINE, DDAB, SuperFect). Successful modification was determined by PCR amplification of DNA or mRNA-derived cDNA followed by Kpnl digestion. The results of these studies showed that SFHR can be used as a gene therapy to introduce specific modifications into the cells of clinically affected organs and that the cells will express the new sequence.

Original languageEnglish
Pages (from-to)961-965
Number of pages5
JournalGene Therapy
Volume8
Issue number12
DOIs
Publication statusPublished - 2001

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Lung
Genetic Therapy
DNA
Inbred CFTR Mouse
Exons
Gene Targeting
Regulator Genes
Digestion
Complementary DNA
Epithelial Cells
Polymerase Chain Reaction
Messenger RNA

Keywords

  • Cystic fibrosis
  • DNA delivery vehicles
  • Gene targeting
  • Gene therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR. / Goncz, K. K.; Colosimo, A.; Dallapiccola, B.; Gagné, L.; Hong, K.; Novelli, G.; Papahadjopoulos, D.; Sawa, T.; Schreier, H.; Wiener-Kronish, J.; Xu, Z.; Gruenert, D. C.

In: Gene Therapy, Vol. 8, No. 12, 2001, p. 961-965.

Research output: Contribution to journalArticle

Goncz, KK, Colosimo, A, Dallapiccola, B, Gagné, L, Hong, K, Novelli, G, Papahadjopoulos, D, Sawa, T, Schreier, H, Wiener-Kronish, J, Xu, Z & Gruenert, DC 2001, 'Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR', Gene Therapy, vol. 8, no. 12, pp. 961-965. https://doi.org/10.1038/sj.gt.3301476
Goncz, K. K. ; Colosimo, A. ; Dallapiccola, B. ; Gagné, L. ; Hong, K. ; Novelli, G. ; Papahadjopoulos, D. ; Sawa, T. ; Schreier, H. ; Wiener-Kronish, J. ; Xu, Z. ; Gruenert, D. C. / Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR. In: Gene Therapy. 2001 ; Vol. 8, No. 12. pp. 961-965.
@article{724e6aa48e8b433987193022ad079d06,
title = "Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR",
abstract = "The development of gene targeting strategies for specific modification of genomic DNA in human somatic cells has provided a potential gene therapy for the treatment of inherited diseases. One approach, small fragment homologous replacement (SFHR), directly targets and modifies specific genomic sequences with small fragments of exogenous DNA (400-800 bp) that are homologous to genomic sequences except for the desired modification. This approach has been effective for the in vitro modification of exon 10 in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human airway epithelial cells. As another step in the development of SFHR for gene therapy, studies were carried out to target and modify specific genomic sequences in exon 10 of the mouse CFTR (mCFTR) in vivo. Small DNA fragments (783 bp), homologous to mCFTR except for a 3-bp deletion (ΔF508) and a silent mutation which introduces a unique restriction site (Kpnl), were instilled into the lungs of normal mice using four different DNA vehicles (AVE, LipofectAMINE, DDAB, SuperFect). Successful modification was determined by PCR amplification of DNA or mRNA-derived cDNA followed by Kpnl digestion. The results of these studies showed that SFHR can be used as a gene therapy to introduce specific modifications into the cells of clinically affected organs and that the cells will express the new sequence.",
keywords = "Cystic fibrosis, DNA delivery vehicles, Gene targeting, Gene therapy",
author = "Goncz, {K. K.} and A. Colosimo and B. Dallapiccola and L. Gagn{\'e} and K. Hong and G. Novelli and D. Papahadjopoulos and T. Sawa and H. Schreier and J. Wiener-Kronish and Z. Xu and Gruenert, {D. C.}",
year = "2001",
doi = "10.1038/sj.gt.3301476",
language = "English",
volume = "8",
pages = "961--965",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR

AU - Goncz, K. K.

AU - Colosimo, A.

AU - Dallapiccola, B.

AU - Gagné, L.

AU - Hong, K.

AU - Novelli, G.

AU - Papahadjopoulos, D.

AU - Sawa, T.

AU - Schreier, H.

AU - Wiener-Kronish, J.

AU - Xu, Z.

AU - Gruenert, D. C.

PY - 2001

Y1 - 2001

N2 - The development of gene targeting strategies for specific modification of genomic DNA in human somatic cells has provided a potential gene therapy for the treatment of inherited diseases. One approach, small fragment homologous replacement (SFHR), directly targets and modifies specific genomic sequences with small fragments of exogenous DNA (400-800 bp) that are homologous to genomic sequences except for the desired modification. This approach has been effective for the in vitro modification of exon 10 in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human airway epithelial cells. As another step in the development of SFHR for gene therapy, studies were carried out to target and modify specific genomic sequences in exon 10 of the mouse CFTR (mCFTR) in vivo. Small DNA fragments (783 bp), homologous to mCFTR except for a 3-bp deletion (ΔF508) and a silent mutation which introduces a unique restriction site (Kpnl), were instilled into the lungs of normal mice using four different DNA vehicles (AVE, LipofectAMINE, DDAB, SuperFect). Successful modification was determined by PCR amplification of DNA or mRNA-derived cDNA followed by Kpnl digestion. The results of these studies showed that SFHR can be used as a gene therapy to introduce specific modifications into the cells of clinically affected organs and that the cells will express the new sequence.

AB - The development of gene targeting strategies for specific modification of genomic DNA in human somatic cells has provided a potential gene therapy for the treatment of inherited diseases. One approach, small fragment homologous replacement (SFHR), directly targets and modifies specific genomic sequences with small fragments of exogenous DNA (400-800 bp) that are homologous to genomic sequences except for the desired modification. This approach has been effective for the in vitro modification of exon 10 in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human airway epithelial cells. As another step in the development of SFHR for gene therapy, studies were carried out to target and modify specific genomic sequences in exon 10 of the mouse CFTR (mCFTR) in vivo. Small DNA fragments (783 bp), homologous to mCFTR except for a 3-bp deletion (ΔF508) and a silent mutation which introduces a unique restriction site (Kpnl), were instilled into the lungs of normal mice using four different DNA vehicles (AVE, LipofectAMINE, DDAB, SuperFect). Successful modification was determined by PCR amplification of DNA or mRNA-derived cDNA followed by Kpnl digestion. The results of these studies showed that SFHR can be used as a gene therapy to introduce specific modifications into the cells of clinically affected organs and that the cells will express the new sequence.

KW - Cystic fibrosis

KW - DNA delivery vehicles

KW - Gene targeting

KW - Gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0034743499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034743499&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301476

DO - 10.1038/sj.gt.3301476

M3 - Article

C2 - 11426337

AN - SCOPUS:0034743499

VL - 8

SP - 961

EP - 965

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 12

ER -